View ValuationRepublic Technologies 将来の成長Future 基準チェック /06現在、 Republic Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Software 収益成長19.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 14Republic Technologies Inc. announced that it expects to receive CAD 4.08523 million in fundingRepublic Technologies Inc. announced a non-brokered private placement offering of up to 14,087,000 special warrants at an issue price of CAD 0.29 for the proceeds of CAD 4,085,230 on February 13, 2026. Each Special Warrant will automatically convert, for no additional consideration, into one common share in the capital of the Company. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Securities issued under the Offering will be subject to a four-month hold period from the date of closing of the Offering.お知らせ • Feb 07Republic Technologies Inc. Appoints Xinbo Zhu as Special Advisor to the Board and Member of Infrastructure and Energy Advisory CommitteeRepublic Technologies Inc. announced the appointment of Xinbo Zhu as Special Advisor to the Board and member of the newly formed Infrastructure and Energy Advisory Committee (IEAC). Mr. Zhu currently serves as Senior Vice President and Chief Financial Officer of Canadian Solar Inc., a global renewable energy company with operations spanning manufacturing, project development, and asset ownership across multiple continents. Over more than two decades, he has held senior executive roles overseeing finance, risk, supply chain, and investment decision-making in complex, capital-intensive environments. Mr. Zhu holds an MBA from the Rotman School of Management at the University of Toronto and a Master of Engineering in Electronic Engineering from Shanghai Jiao Tong University. His career spans senior leadership roles in public companies and multinational organizations across North America and Asia, with a consistent focus on disciplined capital allocation and risk-adjusted growth. The Company will leverage Mr. Zhu’s expertise to help guide its efforts in creating scalable, Ethereum backed, digital infrastructure. His experience will offer valuable advice in the Company’s decision-making efforts as it executes on its business plan and evaluates future growth opportunities.お知らせ • Oct 21Republic Technologies Inc. announced that it expects to receive CAD 126.432 million in fundingRepublic Technologies Inc. announced that it has entered into a financing agreement with an institutional investor to issue secured convertible notes in the principal amount of CAD 140,480,000 at discount of 10% and warrants for gross proceeds of CAD 126,432,000 on October 20, 2025. The company will issue convertible notes for gross proceeds of CAD 14,048,000 in its initial tranche. The convertible note will bear 0% interest and have term of 24 months. The notes will be convertible into common shares. In connection with the first drawdown, the company proposes to issue to the investor up to 28,000,000 common share purchase warrants, exercisable to purchase common shares at a price of CAD 0.50 per common share for a period of 5 years from the date of issuance. The closing of the first drawdown is expected to occur on or about October 24, 2025 and will be subject to customary conditions. The first drawdown convertible note, warrants and any common shares issuable upon conversion of the note or exercise of warrants will be subject to a statutory hold period of four months plus one day in accordance with applicable Canadian securities laws. The company may pay customary finder's fees in connection with the proposed financing, subject to CSE policies. No insiders of the company are expected to participate in the proposed financing.New Risk • Sep 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$4.50m (US$3.25m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$363k free cash flow). Negative equity (-CA$278k). Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.50m market cap, or US$3.25m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$363k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$363k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$278k). Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$16.5m market cap, or US$12.0m).お知らせ • Jun 23Beyond Medical Technologies Inc. announced that it has received CAD 2.09875 million in fundingOn June 23, 2025, Beyond Medical Technologies Inc. closed the transaction. The company announced that it has issued CAD 418,750in second and final tranche. The Notes are convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.53 per share. The Notes have a 12-month term and do not bear interest. All securities issued under the Financing are subject to a statutory hold period in accordance with applicable securities laws. The company has raised CAD 2,098,750 in the transaction.お知らせ • May 13Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025. Location: british columbia, vancouver Canadaお知らせ • May 07Beyond Medical Technologies Inc. announced that it expects to receive CAD 2.5 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement that it will issue senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 1,600,000 which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.41 and senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 900,000, which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of the lesser of CAD 0.53 for the aggregate gross proceeds of up to CAD 2,500,000 on May 6, 2025. The Notes will be issued with a term of 12 months. In the event the Non-Interest Bearing Notes are not converted by the holder during the term, the Company will pay a 24% premium on the principal outstanding. The Discounted Conversion Notes will automatically convert into common shares of the Company in the event the 10-day volume weighted average price of the common shares exceeds CAD 1.06. In the event the Discounted Conversion Notes are not converted by the holder during the term, the Company will pay a 15% premium on the principal outstanding. All securities issued under the Financing will be subject to a statutory hold period in accordance with applicable securities laws.お知らせ • Apr 15Beyond Medical Technologies Inc. announced that it has received CAD 0.979657 million in fundingOn April 14, 2025. Beyond Medical Technologies Inc. closed the transaction and issued 8,987,677 units at a price of CAD 0.109 per unit for gross proceeds of CAD 979,656.793. Each unit comprising one common share in the capital of the company. The securities are subject to a statutory hold period of four months and one day from the date of issuance. Tianrui Zhang holding more than 10% of the company's outstanding shares, acquired or exercised control over a total of 1,100,000 units under the private placement. Immediately before completion of the private placement, Zhang beneficially owned and controlled 2,967,800 common shares and 1,467,800 common share purchase warrants, representing 12.73% of the company's issued and outstanding common shares on a non-diluted and 17.90% on a partially diluted basis, assuming exercise of his warrants. Immediately after completion of the private placement, Zhang beneficially owned and controlled a total of 4,067,800 common shares and 1,467,800 common share purchase warrants, representing 12.59% of the company's issued and outstanding common shares on a non-diluted basis and 16.39% on a partially diluted basis, assuming exercise of his warrants.お知らせ • Apr 02Beyond Medical Technologies Inc. announced that it expects to receive CAD 1.1726 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement of up to 9,020,000 common shares at a price of CAD 0.13 per share for the gross proceeds of up to CAD 1,172,600 on April 1, 2025. The securities will be subject to a statutory hold period of four months and one day from the date of issuance. The offering remains subject to approval by the Canadian Securities Exchange (CSE). The Company may pay finder's fees to eligible finders in connection with the offering, subject to compliance with applicable securities laws and CSE policies.New Risk • Mar 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 95% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (93% average weekly change). Negative equity (-CA$536k). Shareholders have been substantially diluted in the past year (95% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.56m market cap, or US$1.08m).お知らせ • Feb 27Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million.Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million on February 26, 2025. The consideration consists of 11.25 million shares of Beyond Medical Technologies Inc. to be issued for common equity of Elite Horizon Management, Inc. Completion of the Proposed Transaction will be subject to a number of conditions precedent, including, but not limited to: (i) satisfactory completion of due diligence investigations by each of the Company and Horizon; (ii) the negotiation and execution of a definitive agreement which will contain terms and conditions customary for transactions of this nature (the "Definitive Agreement") on or before March 31, 2025; and (iii) receipt of all requisite regulatory and third party approvals, including the approval of the Canadian Securities Exchange.お知らせ • Feb 14+ 1 more updateBeyond Medical Technologies Inc. Appoints Steven McAuley to the Board of DirectorsBeyond Medical Technologies Inc. announces the appointment of Mr. Steven McAuley to its Board of Directors. Mr. McAuley brings decades of experience in corporate governance and operational strategy, further enhancing the company's leadership team. His appointment aligns with Beyond Medical's commitment to strong governance and strategic growth.お知らせ • Feb 13Beyond Medical Technologies Inc. announced that it expects to receive CAD 0.375 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement that it will issue up to 7,500,000 units of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 375,000 on February 11, 2025. Each Unit will consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Share at a price of $0.075 per Share for a period of 24 months from the date of issuance. The securities offered pursuant to the Offering will be subject to a statutory hold period of four months and a day from the date of issuance. Finder's fees may be payable in connection with the Offering, all in accordance with the policies of the Canadian Securities Exchange.お知らせ • Feb 06Beyond Medical Technologies Inc Announces CEO ChangesBeyond Medical Technologies Inc. announced that it has appointed Daniel Liu as Chief Executive Officer of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors.お知らせ • Feb 05Beyond Medical Technologies Inc. Announces Board ChangesBeyond Medical Technologies Inc. announced that it has appointed Daniel Liu as a director of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors.Board Change • Nov 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Michael Kelly was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 08Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Michael Kelly was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 26+ 1 more updateBeyond Medical Technologies Inc. Announces Chief Financial Officer ChangesBeyond Medical Technologies Inc. announced that Zara Kanji- Aquino has resigned as the Chief Financial Officer of the Company. Following Ms. Kanji-Aquino's resignation, the Company has appointed Jatin Bakshi as its Chief Financial Officer. Mr. Bakshi, CPA, FCA(India), MBA has more than 8 years of versatile experience in accounting, finance and taxation out of which 7 years is in public practice in Canada and abroad. After obtaining a CA designation from the Institute of Chartered Accountants of India in 2016, Mr. Bakshi worked in auditing and financial reporting for a public company in India. Subsequently, Mr. Bakshi started a practice firm in India to provide auditing and taxation services to small manufacturing and service-based businesses. Having worked with businesses from vastly different sectors, Mr. Bakshi developed an in-depth understanding of financial reporting and the regulatory environment. Mr. Bakshi earned his CPA designation in 2022 and since then he has been involved with accounting and compliance of various publicly listed companies.New Risk • Nov 30New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$79k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$667k free cash flow). Shares are highly illiquid. Negative equity (-CA$79k). Revenue is less than US$1m. Market cap is less than US$10m (CA$430.1k market cap, or US$316.6k).お知らせ • Jan 24Beyond Medical Technologies Inc., Annual General Meeting, Apr 14, 2023Beyond Medical Technologies Inc., Annual General Meeting, Apr 14, 2023.Reported Earnings • Nov 25Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.004 loss per share (in line with 3Q 2021). Revenue: CA$21.9k (down 92% from 3Q 2021). Net loss: CA$356.2k (loss widened 17% from 3Q 2021).Reported Earnings • Aug 31Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2021)Second quarter 2022 results: CA$0.003 loss per share (up from CA$0.005 loss in 2Q 2021). Revenue: CA$35.4k (down 87% from 2Q 2021). Net loss: CA$225.6k (loss narrowed 43% from 2Q 2021).Reported Earnings • May 28First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.012 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (up from CA$0.012 loss in 1Q 2021). Revenue: CA$126.3k (down 52% from 1Q 2021). Net loss: CA$460.9k (loss narrowed 43% from 1Q 2021).お知らせ • Mar 13Beyond Medical Technologies Inc. announced that it has received CAD 2.774938 million in fundingOn March 11, 2021, Beyond Medical Technologies Inc. (OTCPK:DOCK.F) closed the transaction. The company received approximately CAD 2,774,937.50 in the transaction. The company has received its second and final tranche. The company has issued 11,619,500 units for gross proceeds of CAD 1,452,437.50. Each warrant is exercisable to purchase one additional share until March 11, 2023. The warrants are subject to an acceleration right of the company. All securities issued in connection with the first tranche of the transaction are subject to a statutory hold period expiring on July 12, 2021. The company paid aggregate cash finders' fees totalling CAD 41,746.25 and issued 333,970 finders’ warrants. Each finders’ warrant entitles the holder to purchase one share at an exercise price of CAD 0.20 per finders’ warrant share until March 11, 2023.Executive Departure • Feb 16CTO, Director & Co-Founder Bharat Bhushan has left the companyOn the 11th of February, Bharat Bhushan's tenure as CTO, Director & Co-Founder ended after 3.3 years in the role. As of December 2020, Bharat personally held 3.70m shares (CA$426k worth at the time). Bharat is the only executive to leave the company over the last 12 months.お知らせ • Feb 12Beyond Medical Technologies Inc. Announces Board ChangesBeyond Medical Technologies Inc. announced the appointment of Michael Kelly to the Company's board of directors, effective February 11, 2021. Mr. Kelly replaces Bharat Bhushan, who has resigned as the Chief Technology Officer and as a director of the Company in order to pursue other opportunities. Mr. Kelly served over 17 years as a Military Police Officer with the Canadian Armed Forces. In 2001, Mr. Kelly left the Armed Forces to pursue a career with the Royal Canadian Mounted Police, serving in communities across British Columbia. Mr. Kelly retired from active service in 2015 and pursued his new passion of entrepreneurship. He has been a strategic partner to Bull Run Capital Inc. since 2015 and has become a respected investor and businessman in Kelowna, British Columbia. Mr. Kelly brings a straightforward business approach with boundless enthusiasm and energy to the Company's board of directors.Is New 90 Day High Low • Feb 11New 90-day high: CA$0.21The company is up 95% from its price of CA$0.11 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 90% over the same period.お知らせ • Feb 10Beyond Medical Technologies Inc. Announces Its Letter of Intent with Kayan Health LimitedBeyond Medical Technologies Inc. announced its letter of intent with Kayan Health Limited. Kayan Health has signed a Memorandum of Understanding with Predictiv Care Inc. This partnership between Kayan Health and Predictiv will provide a personalized approach to predictive medicine and will significantly increase the patient-physician relationship by going far beyond medicine and healthcare as they know it. Under the terms of the MOU, Kayan Health and Predictiv will collaborate to integrate their technologies delivering a range of DNA-Based AI-powered services ensuring that clinics and healthcare providers are better equipped to support their patients. In addition to Kayan's AI-driven patient triaging platform, Predictiv will enable Kayan to offer a pre-diagnosis based on the patient's symptoms combined with their personal genome. This will provide the opportunity to identify at-risk patients early on and increase the rates of successful treatments. It will also enable genetics-based vital monitoring through wearable technology and medical-grade diagnostic devices. Patients are now empowered to enhance their quality of life by closely monitoring their symptoms and having secure, on-demand access to their physician. Furthermore, Kayan Health's telehealth platform will assist patients with the early detection and diagnosis of more than 16,000 diseases, provide them with valuable information about their health and help streamline their communication with their doctor. Utilizing AI-powered services to connect data to real people, Kayan Health aims to democratize the healthcare system.お知らせ • Jan 15+ 1 more updateBeyond Medical Technologies Inc. (OTCPK:MICW.F) entered into a letter of intent to acquire Kayan Health Limited for CAD 6 million.Beyond Medical Technologies Inc. (OTCPK:MICW.F) entered into a letter of intent to acquire Kayan Health Limited for CAD 6 million on January 14, 2021. The consideration is payable in shares of Beyond Medical Technologies. Pursuant to the terms, CAD 4 million in shares is payable at closing and remaining CAD 2 million in shares will be payable upon achievement of performance milestones. Post-completion, Kayan Health will become a wholly-owned subsidiary of Beyond Medical Technologies. Post-completion, Beyond Medical Technologies will appoint two nominees of Kayan Health in its board. The transaction is subject to certain closing conditions including, without limitation, completion of customary due diligence, negotiation and execution of a definitive agreement on or before April 30, 2021 and receipt of all required regulatory and the third party approvals.お知らせ • Oct 08Micron Waste Technologies Inc. Announces Micron Technologies Inc. Has Met the American Society for Testing and Materials F2100 – 19 Standard Specification for Performance of Materials Used in Medical Face MasksMicron Waste Technologies Inc. announced that its wholly-owned subsidiary, Micron Technologies Inc. has met the American Society for Testing and Materials F2100 – 19 Standard Specification for Performance of Materials Used in Medical Face Masks (the "ASTM F2100 Standards") level three certification requirements (the "ASTM Level Three Requirements") for its 3-ply surgical face masks. Micron Technologies is currently utilizing the Company's facility in Delta, British Columbia to manufacture the 3-ply surgical masks. Among other technical specifications, the ASTM Level Three Requirements ensure that medical face masks have a bacterial filtration efficiency of greater than or equal to 98%, which is the highest level of performance under the ASTM F2100 Standards. Both Health Canada and the United States Food & Drug Administration recognize the ASTM F2100 Standards. The achievement of meeting the ASTM Level Three Requirements is a significant milestone for Micron Technologies that will enable it to continue to meet the needs of the medical industry, various public and private organizations, as well as the general public. Micron Technologies has also received its N95 mask-manufacturing machine and expects production to begin in October. Micron Technologies plans to send N95 mask samples to the National Institute for Occupational Safety and Health for certification to be able to sell medical grade N95 masks.お知らせ • Sep 21Micron Technologies Inc. Starts to Manufacture Made in Canada Face Masks Pursuant to Its Medical Device Establishment LicenseMicron Technologies Inc. has received and installed its 3-ply mask-manufacturing machine and associated equipment. The Company, through Micron Technologies, will manufacture face masks pursuant to its Medical Device Establishment License ("MDEL") from Health Canada. The MDEL permits Micron Technologies to manufacture Class I products, which include face masks, at the Company's facility in Delta, British Columbia. The MDEL is issued by the Minister of Health in accordance with the Medical Device Regulations of the Food and Drugs Act. The Company has also received its N95 mask-manufacturing machine and expects production to begin in early October. Additionally, the Company plans to send N95 mask samples to the National Institute for Occupational Safety and Health for certification to be able to sell medical grade N95 masks. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Republic Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:DOCT - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2025N/A-2-1-1N/A6/30/2025N/A-2-1-1N/A3/31/2025N/A000N/A12/31/2024N/A000N/A9/30/2024N/A000N/A6/30/2024N/A000N/A3/31/2024N/A000N/A12/31/2023N/A-1-1-1N/A9/30/2023N/A-1-1-1N/A6/30/2023N/A-1-1-1N/A3/31/2023N/A-1-1-1N/A12/31/2022N/A-1-1-1N/A9/30/2022-1-1-1-1N/A6/30/2022-1-1-1-1N/A3/31/20220-1-1-1N/A12/31/2021N/A-2-1-1N/A9/30/20211-6-1-2N/A6/30/20211-6-2-2N/A3/31/20210-7-3-2N/A12/31/20200-7-2-2N/A9/30/20200-5-3-2N/A6/30/2020N/A-5-3-2N/A3/31/2020N/A-6-3-2N/A12/31/2019N/A-5-4-2N/A9/30/2019N/A-3-4-2N/A6/30/2019N/A-3N/A-2N/A3/31/2019N/A-3N/A-2N/A12/31/2018N/A-3N/A-2N/A9/30/2018N/A-10N/A-2N/A6/30/2018N/A-10N/A-2N/A3/31/2018N/A-9N/A-2N/A12/31/2017N/A-9N/A-1N/A9/30/2017N/A-1N/A-1N/A6/30/2017N/A-1N/A0N/A3/31/2017N/A0N/A0N/A12/31/2016N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DOCTの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: DOCTの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: DOCTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: DOCTの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: DOCTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DOCTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/17 00:55終値2026/05/15 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Republic Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 14Republic Technologies Inc. announced that it expects to receive CAD 4.08523 million in fundingRepublic Technologies Inc. announced a non-brokered private placement offering of up to 14,087,000 special warrants at an issue price of CAD 0.29 for the proceeds of CAD 4,085,230 on February 13, 2026. Each Special Warrant will automatically convert, for no additional consideration, into one common share in the capital of the Company. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Securities issued under the Offering will be subject to a four-month hold period from the date of closing of the Offering.
お知らせ • Feb 07Republic Technologies Inc. Appoints Xinbo Zhu as Special Advisor to the Board and Member of Infrastructure and Energy Advisory CommitteeRepublic Technologies Inc. announced the appointment of Xinbo Zhu as Special Advisor to the Board and member of the newly formed Infrastructure and Energy Advisory Committee (IEAC). Mr. Zhu currently serves as Senior Vice President and Chief Financial Officer of Canadian Solar Inc., a global renewable energy company with operations spanning manufacturing, project development, and asset ownership across multiple continents. Over more than two decades, he has held senior executive roles overseeing finance, risk, supply chain, and investment decision-making in complex, capital-intensive environments. Mr. Zhu holds an MBA from the Rotman School of Management at the University of Toronto and a Master of Engineering in Electronic Engineering from Shanghai Jiao Tong University. His career spans senior leadership roles in public companies and multinational organizations across North America and Asia, with a consistent focus on disciplined capital allocation and risk-adjusted growth. The Company will leverage Mr. Zhu’s expertise to help guide its efforts in creating scalable, Ethereum backed, digital infrastructure. His experience will offer valuable advice in the Company’s decision-making efforts as it executes on its business plan and evaluates future growth opportunities.
お知らせ • Oct 21Republic Technologies Inc. announced that it expects to receive CAD 126.432 million in fundingRepublic Technologies Inc. announced that it has entered into a financing agreement with an institutional investor to issue secured convertible notes in the principal amount of CAD 140,480,000 at discount of 10% and warrants for gross proceeds of CAD 126,432,000 on October 20, 2025. The company will issue convertible notes for gross proceeds of CAD 14,048,000 in its initial tranche. The convertible note will bear 0% interest and have term of 24 months. The notes will be convertible into common shares. In connection with the first drawdown, the company proposes to issue to the investor up to 28,000,000 common share purchase warrants, exercisable to purchase common shares at a price of CAD 0.50 per common share for a period of 5 years from the date of issuance. The closing of the first drawdown is expected to occur on or about October 24, 2025 and will be subject to customary conditions. The first drawdown convertible note, warrants and any common shares issuable upon conversion of the note or exercise of warrants will be subject to a statutory hold period of four months plus one day in accordance with applicable Canadian securities laws. The company may pay customary finder's fees in connection with the proposed financing, subject to CSE policies. No insiders of the company are expected to participate in the proposed financing.
New Risk • Sep 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$4.50m (US$3.25m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$363k free cash flow). Negative equity (-CA$278k). Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.50m market cap, or US$3.25m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$363k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$363k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$278k). Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$16.5m market cap, or US$12.0m).
お知らせ • Jun 23Beyond Medical Technologies Inc. announced that it has received CAD 2.09875 million in fundingOn June 23, 2025, Beyond Medical Technologies Inc. closed the transaction. The company announced that it has issued CAD 418,750in second and final tranche. The Notes are convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.53 per share. The Notes have a 12-month term and do not bear interest. All securities issued under the Financing are subject to a statutory hold period in accordance with applicable securities laws. The company has raised CAD 2,098,750 in the transaction.
お知らせ • May 13Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025Beyond Medical Technologies Inc., Annual General Meeting, Jul 09, 2025. Location: british columbia, vancouver Canada
お知らせ • May 07Beyond Medical Technologies Inc. announced that it expects to receive CAD 2.5 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement that it will issue senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 1,600,000 which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of CAD 0.41 and senior secured non-interest bearing convertible notes in the aggregate principal amount of CAD 900,000, which principal amount will be convertible into common shares of the Company at the option of the holder at a conversion price of the lesser of CAD 0.53 for the aggregate gross proceeds of up to CAD 2,500,000 on May 6, 2025. The Notes will be issued with a term of 12 months. In the event the Non-Interest Bearing Notes are not converted by the holder during the term, the Company will pay a 24% premium on the principal outstanding. The Discounted Conversion Notes will automatically convert into common shares of the Company in the event the 10-day volume weighted average price of the common shares exceeds CAD 1.06. In the event the Discounted Conversion Notes are not converted by the holder during the term, the Company will pay a 15% premium on the principal outstanding. All securities issued under the Financing will be subject to a statutory hold period in accordance with applicable securities laws.
お知らせ • Apr 15Beyond Medical Technologies Inc. announced that it has received CAD 0.979657 million in fundingOn April 14, 2025. Beyond Medical Technologies Inc. closed the transaction and issued 8,987,677 units at a price of CAD 0.109 per unit for gross proceeds of CAD 979,656.793. Each unit comprising one common share in the capital of the company. The securities are subject to a statutory hold period of four months and one day from the date of issuance. Tianrui Zhang holding more than 10% of the company's outstanding shares, acquired or exercised control over a total of 1,100,000 units under the private placement. Immediately before completion of the private placement, Zhang beneficially owned and controlled 2,967,800 common shares and 1,467,800 common share purchase warrants, representing 12.73% of the company's issued and outstanding common shares on a non-diluted and 17.90% on a partially diluted basis, assuming exercise of his warrants. Immediately after completion of the private placement, Zhang beneficially owned and controlled a total of 4,067,800 common shares and 1,467,800 common share purchase warrants, representing 12.59% of the company's issued and outstanding common shares on a non-diluted basis and 16.39% on a partially diluted basis, assuming exercise of his warrants.
お知らせ • Apr 02Beyond Medical Technologies Inc. announced that it expects to receive CAD 1.1726 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement of up to 9,020,000 common shares at a price of CAD 0.13 per share for the gross proceeds of up to CAD 1,172,600 on April 1, 2025. The securities will be subject to a statutory hold period of four months and one day from the date of issuance. The offering remains subject to approval by the Canadian Securities Exchange (CSE). The Company may pay finder's fees to eligible finders in connection with the offering, subject to compliance with applicable securities laws and CSE policies.
New Risk • Mar 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 95% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (93% average weekly change). Negative equity (-CA$536k). Shareholders have been substantially diluted in the past year (95% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.56m market cap, or US$1.08m).
お知らせ • Feb 27Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million.Beyond Medical Technologies Inc. (OTCPK:DOCK.F) entered into a non-binding letter of intent to acquire Elite Horizon Management, Inc. for CAD 1.13 million on February 26, 2025. The consideration consists of 11.25 million shares of Beyond Medical Technologies Inc. to be issued for common equity of Elite Horizon Management, Inc. Completion of the Proposed Transaction will be subject to a number of conditions precedent, including, but not limited to: (i) satisfactory completion of due diligence investigations by each of the Company and Horizon; (ii) the negotiation and execution of a definitive agreement which will contain terms and conditions customary for transactions of this nature (the "Definitive Agreement") on or before March 31, 2025; and (iii) receipt of all requisite regulatory and third party approvals, including the approval of the Canadian Securities Exchange.
お知らせ • Feb 14+ 1 more updateBeyond Medical Technologies Inc. Appoints Steven McAuley to the Board of DirectorsBeyond Medical Technologies Inc. announces the appointment of Mr. Steven McAuley to its Board of Directors. Mr. McAuley brings decades of experience in corporate governance and operational strategy, further enhancing the company's leadership team. His appointment aligns with Beyond Medical's commitment to strong governance and strategic growth.
お知らせ • Feb 13Beyond Medical Technologies Inc. announced that it expects to receive CAD 0.375 million in fundingBeyond Medical Technologies Inc. announced a non-brokered private placement that it will issue up to 7,500,000 units of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 375,000 on February 11, 2025. Each Unit will consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Share at a price of $0.075 per Share for a period of 24 months from the date of issuance. The securities offered pursuant to the Offering will be subject to a statutory hold period of four months and a day from the date of issuance. Finder's fees may be payable in connection with the Offering, all in accordance with the policies of the Canadian Securities Exchange.
お知らせ • Feb 06Beyond Medical Technologies Inc Announces CEO ChangesBeyond Medical Technologies Inc. announced that it has appointed Daniel Liu as Chief Executive Officer of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors.
お知らせ • Feb 05Beyond Medical Technologies Inc. Announces Board ChangesBeyond Medical Technologies Inc. announced that it has appointed Daniel Liu as a director of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi's resignation as Chief Executive Officer and as a director, effective January 30, 2025. Mr. Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors.
Board Change • Nov 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Michael Kelly was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 08Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024Beyond Medical Technologies Inc., Annual General Meeting, Jul 10, 2024.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Michael Kelly was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 26+ 1 more updateBeyond Medical Technologies Inc. Announces Chief Financial Officer ChangesBeyond Medical Technologies Inc. announced that Zara Kanji- Aquino has resigned as the Chief Financial Officer of the Company. Following Ms. Kanji-Aquino's resignation, the Company has appointed Jatin Bakshi as its Chief Financial Officer. Mr. Bakshi, CPA, FCA(India), MBA has more than 8 years of versatile experience in accounting, finance and taxation out of which 7 years is in public practice in Canada and abroad. After obtaining a CA designation from the Institute of Chartered Accountants of India in 2016, Mr. Bakshi worked in auditing and financial reporting for a public company in India. Subsequently, Mr. Bakshi started a practice firm in India to provide auditing and taxation services to small manufacturing and service-based businesses. Having worked with businesses from vastly different sectors, Mr. Bakshi developed an in-depth understanding of financial reporting and the regulatory environment. Mr. Bakshi earned his CPA designation in 2022 and since then he has been involved with accounting and compliance of various publicly listed companies.
New Risk • Nov 30New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$79k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$667k free cash flow). Shares are highly illiquid. Negative equity (-CA$79k). Revenue is less than US$1m. Market cap is less than US$10m (CA$430.1k market cap, or US$316.6k).
お知らせ • Jan 24Beyond Medical Technologies Inc., Annual General Meeting, Apr 14, 2023Beyond Medical Technologies Inc., Annual General Meeting, Apr 14, 2023.
Reported Earnings • Nov 25Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.004 loss per share (in line with 3Q 2021). Revenue: CA$21.9k (down 92% from 3Q 2021). Net loss: CA$356.2k (loss widened 17% from 3Q 2021).
Reported Earnings • Aug 31Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2021)Second quarter 2022 results: CA$0.003 loss per share (up from CA$0.005 loss in 2Q 2021). Revenue: CA$35.4k (down 87% from 2Q 2021). Net loss: CA$225.6k (loss narrowed 43% from 2Q 2021).
Reported Earnings • May 28First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.012 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (up from CA$0.012 loss in 1Q 2021). Revenue: CA$126.3k (down 52% from 1Q 2021). Net loss: CA$460.9k (loss narrowed 43% from 1Q 2021).
お知らせ • Mar 13Beyond Medical Technologies Inc. announced that it has received CAD 2.774938 million in fundingOn March 11, 2021, Beyond Medical Technologies Inc. (OTCPK:DOCK.F) closed the transaction. The company received approximately CAD 2,774,937.50 in the transaction. The company has received its second and final tranche. The company has issued 11,619,500 units for gross proceeds of CAD 1,452,437.50. Each warrant is exercisable to purchase one additional share until March 11, 2023. The warrants are subject to an acceleration right of the company. All securities issued in connection with the first tranche of the transaction are subject to a statutory hold period expiring on July 12, 2021. The company paid aggregate cash finders' fees totalling CAD 41,746.25 and issued 333,970 finders’ warrants. Each finders’ warrant entitles the holder to purchase one share at an exercise price of CAD 0.20 per finders’ warrant share until March 11, 2023.
Executive Departure • Feb 16CTO, Director & Co-Founder Bharat Bhushan has left the companyOn the 11th of February, Bharat Bhushan's tenure as CTO, Director & Co-Founder ended after 3.3 years in the role. As of December 2020, Bharat personally held 3.70m shares (CA$426k worth at the time). Bharat is the only executive to leave the company over the last 12 months.
お知らせ • Feb 12Beyond Medical Technologies Inc. Announces Board ChangesBeyond Medical Technologies Inc. announced the appointment of Michael Kelly to the Company's board of directors, effective February 11, 2021. Mr. Kelly replaces Bharat Bhushan, who has resigned as the Chief Technology Officer and as a director of the Company in order to pursue other opportunities. Mr. Kelly served over 17 years as a Military Police Officer with the Canadian Armed Forces. In 2001, Mr. Kelly left the Armed Forces to pursue a career with the Royal Canadian Mounted Police, serving in communities across British Columbia. Mr. Kelly retired from active service in 2015 and pursued his new passion of entrepreneurship. He has been a strategic partner to Bull Run Capital Inc. since 2015 and has become a respected investor and businessman in Kelowna, British Columbia. Mr. Kelly brings a straightforward business approach with boundless enthusiasm and energy to the Company's board of directors.
Is New 90 Day High Low • Feb 11New 90-day high: CA$0.21The company is up 95% from its price of CA$0.11 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 90% over the same period.
お知らせ • Feb 10Beyond Medical Technologies Inc. Announces Its Letter of Intent with Kayan Health LimitedBeyond Medical Technologies Inc. announced its letter of intent with Kayan Health Limited. Kayan Health has signed a Memorandum of Understanding with Predictiv Care Inc. This partnership between Kayan Health and Predictiv will provide a personalized approach to predictive medicine and will significantly increase the patient-physician relationship by going far beyond medicine and healthcare as they know it. Under the terms of the MOU, Kayan Health and Predictiv will collaborate to integrate their technologies delivering a range of DNA-Based AI-powered services ensuring that clinics and healthcare providers are better equipped to support their patients. In addition to Kayan's AI-driven patient triaging platform, Predictiv will enable Kayan to offer a pre-diagnosis based on the patient's symptoms combined with their personal genome. This will provide the opportunity to identify at-risk patients early on and increase the rates of successful treatments. It will also enable genetics-based vital monitoring through wearable technology and medical-grade diagnostic devices. Patients are now empowered to enhance their quality of life by closely monitoring their symptoms and having secure, on-demand access to their physician. Furthermore, Kayan Health's telehealth platform will assist patients with the early detection and diagnosis of more than 16,000 diseases, provide them with valuable information about their health and help streamline their communication with their doctor. Utilizing AI-powered services to connect data to real people, Kayan Health aims to democratize the healthcare system.
お知らせ • Jan 15+ 1 more updateBeyond Medical Technologies Inc. (OTCPK:MICW.F) entered into a letter of intent to acquire Kayan Health Limited for CAD 6 million.Beyond Medical Technologies Inc. (OTCPK:MICW.F) entered into a letter of intent to acquire Kayan Health Limited for CAD 6 million on January 14, 2021. The consideration is payable in shares of Beyond Medical Technologies. Pursuant to the terms, CAD 4 million in shares is payable at closing and remaining CAD 2 million in shares will be payable upon achievement of performance milestones. Post-completion, Kayan Health will become a wholly-owned subsidiary of Beyond Medical Technologies. Post-completion, Beyond Medical Technologies will appoint two nominees of Kayan Health in its board. The transaction is subject to certain closing conditions including, without limitation, completion of customary due diligence, negotiation and execution of a definitive agreement on or before April 30, 2021 and receipt of all required regulatory and the third party approvals.
お知らせ • Oct 08Micron Waste Technologies Inc. Announces Micron Technologies Inc. Has Met the American Society for Testing and Materials F2100 – 19 Standard Specification for Performance of Materials Used in Medical Face MasksMicron Waste Technologies Inc. announced that its wholly-owned subsidiary, Micron Technologies Inc. has met the American Society for Testing and Materials F2100 – 19 Standard Specification for Performance of Materials Used in Medical Face Masks (the "ASTM F2100 Standards") level three certification requirements (the "ASTM Level Three Requirements") for its 3-ply surgical face masks. Micron Technologies is currently utilizing the Company's facility in Delta, British Columbia to manufacture the 3-ply surgical masks. Among other technical specifications, the ASTM Level Three Requirements ensure that medical face masks have a bacterial filtration efficiency of greater than or equal to 98%, which is the highest level of performance under the ASTM F2100 Standards. Both Health Canada and the United States Food & Drug Administration recognize the ASTM F2100 Standards. The achievement of meeting the ASTM Level Three Requirements is a significant milestone for Micron Technologies that will enable it to continue to meet the needs of the medical industry, various public and private organizations, as well as the general public. Micron Technologies has also received its N95 mask-manufacturing machine and expects production to begin in October. Micron Technologies plans to send N95 mask samples to the National Institute for Occupational Safety and Health for certification to be able to sell medical grade N95 masks.
お知らせ • Sep 21Micron Technologies Inc. Starts to Manufacture Made in Canada Face Masks Pursuant to Its Medical Device Establishment LicenseMicron Technologies Inc. has received and installed its 3-ply mask-manufacturing machine and associated equipment. The Company, through Micron Technologies, will manufacture face masks pursuant to its Medical Device Establishment License ("MDEL") from Health Canada. The MDEL permits Micron Technologies to manufacture Class I products, which include face masks, at the Company's facility in Delta, British Columbia. The MDEL is issued by the Minister of Health in accordance with the Medical Device Regulations of the Food and Drugs Act. The Company has also received its N95 mask-manufacturing machine and expects production to begin in early October. Additionally, the Company plans to send N95 mask samples to the National Institute for Occupational Safety and Health for certification to be able to sell medical grade N95 masks.